Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.70 |
| ▸ | IKBKB | O14920 | 5/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | CHUK | O15111 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31230207 | 1.00 | KEAP1 (0.70) | KEAP1IKBKBCES2CES1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4362930 | 0.98 | KEAP1 (0.68) | KEAP1IKBKBCES2CES1ALDH1A1 | |
| Anthranilamide SCHEMBL4012579 | 0.91 | KEAP1 (0.59) | KEAP1IKBKBCES2CES1ALDH1A1 | |
| SCHEMBL5308529 | 0.84 | IKBKB (0.71) | KEAP1IKBKBCHUKCYP1A2CYP3A4 | |
| SCHEMBL135091 | 0.83 | KEAP1 (1.00) | KEAP1CES2CES1ALDH1A1FADS1 | |
| SCHEMBL29364785 | 0.83 | KEAP1 (1.00) | KEAP1CES2CES1ALDH1A1FADS1 | |
| SCHEMBL148542 | 0.83 | KEAP1 (0.53) | KEAP1IKBKBCES2CES1ALDH1A1 | |
| SCHEMBL29463969 | 0.82 | CES2 (0.52) | KEAP1IKBKBCES2CES1ALDH1A1 | |
| SCHEMBL12070396 | 0.82 | KEAP1 (0.63) | KEAP1IKBKBCES2CES1ALDH1A1 | |
| SCHEMBL9000281 | 0.81 | KEAP1 (0.96) | KEAP1CES2CES1ALDH1A1FADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010957-A | Preparation method of fullerene pyrrolidine quinazolinone | 湖北大学 | 2026-05-12 | — | — | CN | claimed |
| CN-120079371-A | Oxygen vacancy-containing tungsten trioxide catalyst and preparation method and application thereof | 南京理工大学 | 2025-06-03 | — | — | CN | claimed |
| EP-4746972-A1 | DEUTERATED PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137684-A1 | ROCK2 Inhibitors And Uses Thereof | RESTOR PHARMACEUTICALS (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026104681-A1 | NEW SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| CN-122055367-A | 5-Oxo-4, 5-dihydroimidazo [1,5-a ] quinazoline compounds as PI3K [ alpha ] inhibitors | 皮卡维森治疗学股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010957-A | Preparation method of fullerene pyrrolidine quinazolinone | 湖北大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4674841-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| CN-120079371-A | Oxygen vacancy-containing tungsten trioxide catalyst and preparation method and application thereof | 南京理工大学 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025085474-A1 | 5-OXO-4,5-DIHYDROIMIDAZO[1,5-A]QUINAZOLINE COMPOUNDS AS PI3K[ALPHA] INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20050176955-A1 | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-11 | — | — | US | disclosed |
| WO-2005014585-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) | 2005-02-17 | — | — | WO | disclosed |
| EP-1496836-A2 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004080402-A2 | POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR | MERCK & CO. INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| CN-1143855-C | I (ortho)-anthranilamide derivatives as anti-coagulants | ���ֹɷݹ�˾ | 2004-03-31 | — | — | CN | disclosed |
| WO-2003077850-A2 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003077857-A2 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| US-6479499-B1 | INHIBITORS OF TUBULIN POLYMERIZATION | NATIONAL SCIENCE COUNCIL (TW) | 2002-11-12 | — | — | US | disclosed |
| CN-1282329-A | I (ortho)-anthranilamide derivatives as anti-coagulants | SCHERING AG (DE) | 2001-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176955-A1 | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors | CDK8, PNP, HINT1 | KEAP1 3955/4885IKBKB 176/4885CES2 526/4885 |
| US-20260137684-A1 | ROCK2 Inhibitors And Uses Thereof | ROCK2, ROCK1, RHOA | KEAP1 1607/4885IKBKB 1656/4885CES2 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.